CRC is generally considered a heterogenous disease, with mutations in TP53 and KRAS (~40–50% of cases (3,4)), and BRAF (~10% of cases (5)) contributing to aggressive tumors that are difficult to treat. Here, KRAS is linked to colorectal carcinoma.